Climb Bio, Inc.
For the period ended Mar 31, 2025. Filed May 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 14, 2025
CLYM$10.29+16.0%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| Exhibit Number | Description of Exhibit | Form | File No. | Exhibit | Filing Date |
| 2.1 | Agreement and Plan of Merger and Reorganization, dated as of April 10, 2024, by and among the Company, Tango Merger Sub, Inc., Tenet Medicines, Inc. and, solely in his capacity as the Company Equityholder Representative, Stephen Thomas. | 8-K | 001-40708 | 2.1 | 4/11/2024 |
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant. | 10-Q | 001-40708 | 3.1 | 11/12/2024 |
| 3.2 | Amended and Restated Bylaws of the Registrant. | 8-K | 001-40708 | 3.2 | 10/2/2024 |
| 4.1 | Form of common stock certificate of the Registrant. | 10-K | 001-40708 | 4.1 | 3/25/2025 |
| 4.2 | Amended and Restated Investors Rights Agreement, dated May 21, 2021, by and among the Registrant and the investors listed on Schedule A thereto. | S-1 | 333-257980 | 10.1 | 7/16/2021 |
| 10.1† | Technology Transfer and Exclusive License Agreement, dated January 8, 2025, by and between the Registrant and Beijing Mabworks Biotech Co., Ltd. | 10-K | 001-40708 | 10.14 | 3/25/2025 |
| 10.2 | Equity Distribution Agreement, dated as of March 25, 2025, by and between Climb Bio, Inc. and Oppenheimer & Co. Inc. | 8-K | 001-40708 | 1.1 | 3/25/2025 |
| 10.3+ | 2025 Inducement Plan. | S-8 | 333-286303 | 99.3 | 4/1/2025 |
| 10.4*+ | Form of Stock Option Grant Notice under the 2025 Inducement Plan. | ||||
| 10.5*+ | Form of Restricted Stock Unit Award Grant Notice under the 2025 Inducement Plan. | ||||
| 10.6*+ | Non-Employee Director Compensation Policy. | ||||
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1* | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2* | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents | ||||
| 104 | Cover Page formatted as Inline XBRL and contained in Exhibit 101 | ||||
- Filed herewith.
- Indicates management contract or compensatory plan.
† Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.